Drugs / NeoDC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05317325 | Apr 2022 → Dec 2023 | esophageal squamous cell carcinoma | Sichuan University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NeoDC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05317325 ↗ |
| Route | Subcutaneous | “OCDC vaccine and NeoDC vaccine are administered in a prime-boost regimen by subcutaneous injection.” NCT05317325 ↗ |